Mylan Receives Tentative Approval for Combination HIV Treatment Under FDA’s PEPFAR Program

HERTFORDSHIRE, England and PITTSBURGH, Feb. 20, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced receipt of tentative approval from the U.S. Food and Drug Administration (FDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine, and Tenofovir Alafenamide Tablets, 50 mg/200 mg/25 mg. The antiretroviral (ARV) will [...]

By |2018-03-06T22:42:48+00:00February 23rd, 2018|Latest Publications|Comments Off on Mylan Receives Tentative Approval for Combination HIV Treatment Under FDA’s PEPFAR Program